Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
By G. Cairncross, Meihua Wang, E. Shaw, R. Jenkins, D. Brachman, J. Buckner, K. Fink, L. Souhami, N. Laperriere, W. Curran and 1 more. Journal of Clinical Oncology, 2013
1,051 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology, Neurology
View Paper: https://www.semanticscholar.org/paper/fe230c08d6ee274a3f62d00010f70be344611c54
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Molecular Biology
Citations in the corpus
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas (2015, neutral): “Before 2005 38 (14) 10 (12) 18 (13) 10 (18)”
- High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, background): “Long-term follow-up (10 years) of randomised clinical trials demonstrated prolonged survival with (neo)adjuvant PCV chemotherapy (procarbazine, lomustine [CCNU], vincristine) in newly diagnosed anaplastic oligoastrocytoma and oligodendroglioma [40, 41], but benefit was mainly present in prognostical”
- Glioma Subclassifications and Their Clinical Significance (2017, background): “7 years but did not change the survival for 1p/19q-intact tumors [27].”
- Genomic and Functional Approaches to Understanding Cancer Aneuploidy (2018, background): “Low-grade gliomas cluster near glioblastomas, but are characterized by distinct alterations of chromosome 1p loss and chromosome 19q gain correlating with IDH mutation (Cancer Genome Atlas Research Network et al., 2015), a pattern shown to be therapeutically relevant (Cairncross et al., 2013).”
- Glioblastoma: pathology, molecular mechanisms and markers (2015, background): “1 3 patients), 1p and 19q co-deletions in anaplastic oligodendrogliomas, and IDH1/2 mutations, now play major roles in tumor diagnostics and/or clinical decision making [21, 105, 164, 174].”